Brent Hatzis-Schoch - Feb 15, 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Chief Operating Officer and General Counsel
Signature
/s/ Brent Hatzis-Schoch
Stock symbol
BDTX
Transactions as of
Feb 15, 2022
Transactions value $
$0
Form type
4
Date filed
2/17/2022, 03:21 PM
Previous filing
May 13, 2021
Next filing
Feb 15, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +90K $0.00 90K Feb 15, 2022 Common Stock 90K $3.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Officer Title: Chief Operating Officer and General Counsel